Answers are grounded in this paper and cite their sources.
Arabinosyl cytosine (ara-C) was administered by continuous intravenous infusion to children with acute leukemia refractory to conventional chemotherapy. The dosage was 150 mg to 200 mg/M2 of body surface area per 24 hours for 5 days, repeated every 2 weeks. Forty-six children were admitted to this study. Thirty-four had acute lymphocytic leukemia, and 12 had acute myelocytic leukemia. Of the 34 children with acute lymphocytic leukemia, one achieved complete hematologic remission, 3 achieved good partial remission, 9 had inadequate trials of the agent, and 21 failed to show any response to this agent. Of the 12 children with acute myelocytic leukemia, 2 had complete remission, one achieved good partial remission, 5 had inadequate trials of the agent, and 4 failed to show any response. Myelosuppression was the limiting toxicity. Prolonged infusion of ara-C probably offers no advantage over rapid intravenous injections for the induction of remissions in children with acute lymphocytic leukemia.
No takes yet. Share an insight, caveat, or question.
Wang et al. (1970) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: